SupremeCourt

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Sunday, April 21, 2013

Guest Post: Are Genes Eligible for Patents in the United States?

Posted on 10:04 AM by Unknown
Continuing with our coverage of the arguments in the Myriad case, we bring you another guest post from Chris Ohly, a patent litigator and partner at a leading United States law firm. Chris’ article concerns recent arguments in the United States Supreme Court concerning the eligibility of “genes” for patenting under the US Patent Act. As his article reveals, the question presented in the case is “Are human genes patentable?” 

Standard disclaimers apply, which are as follows: the views expressed in his article are entirely his own and do not necessarily reflect the views of his law firm, or of any of its other attorneys or clients. Nothing in this article is intended to provide any form of legal advice. 

Owing to Blogger’s inability to accommodate footnotes, a full copy of the article written by Chris can be downloaded from the SpicyIP website, by clicking on this link over here. Those of you interested in contacting Chris, can email him at trial_lawyer@msn.com

The procedural history of the Myriad case: The Myriad case has been on the quite the roller coaster ride through the judicial system. The case was first heard and decided by the U.S. District Court for the Southern District of New York, from where it was appealed to the Court of Appeals for the Federal Circuit (CAFC). The losing parties at this stage, the American Civil Liberties Union (ACLU) and other individual plaintiffs then sought review before the U.S. Supreme Court through a petition for a writ of certiorari. 

Like in India, review by the U.S. Supreme Court is, in most cases, not available as of right. However unlike the Indian Supreme Court which admits for hearing, literally thousands of cases, the U.S. Supreme Court hears only a few cases, when it exercises its discretion and grants a petition for a writ of certiorari (perhaps 100, less than 5% of the 10,000 petitions annually received by the Court). The votes of four of the nine Supreme Court Justices are required to grant certiorari. In the Indian Supreme Court, benches of two judges take the call on whether a petition should be admitted and honestly, nobody really knows the criteria on the basis of which such petitions are admitted. 

But getting back to the present case, the U.S. Supreme Court granted the ACLU’s petition for certiorari and set aside the judgment of the CAFC, with instructions that the matter be reheard in light of the Supreme Court’s most recent decision in the case of Mayo v. Prometheus. The CAFC reheard the matter and once again came to the same conclusions, as in its earlier opinion. The majority found that the Supreme Court’s decision in Mayo was not really relevant to the Myriad case. 

The losing party, the ACLU, again petitioned the Supreme Court for certiorari and the Supreme Court granted review for one limited question and that is “Are human genes patentable?” 

The parties’ briefs were lengthy. Dozens of briefs were filed by amicic curiae, including important briefs by the United States; Dr. James Watson, the Nobel Prize winning discoverer of the double-helix structure of DNA; Dr. Eric Lander, one of the principal leaders of the Human Genome Product; and Dr. Ananda Mohan Chakrabarty, a famed inventor whose invention of a new bacterium was challenged in an earlier, seminal Supreme Court case. Chris’ article summarizes some of the arguments made in the many briefs filed in the US Supreme Court in Myriad. 

Oral Argument before the U.S. Supreme Court, as is customary, was limited to about one hour, in total unlike the Indian Supreme Court where there is no limit. Note that in the Novartis case, the Indian Supreme Court heard arguments for over 132 hours. Given the importance of the case, the Solicitor General of the U.S. was asked to present the government’s views and if I’m not mistake, this was one of the rare cases where the U.S. Government had taken a view that was contrary to that of the USPTO. 

Chris’ article also focuses on portions of the Oral Argument Transcript, to highlight issues and arguments considered by the Court. The decision in Myriad will have profound impact in US patent law, particularly in future biologic patenting and related litigation. A final judgement is expected to be delivered by the end of the Supreme Court’s current term, in June 2013. 

A copy of the oral argument transcript can be found hereand copies of the briefs filed in Myriad case can be found here.
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in biotech, gene sequences, Guest post, Patent, SpicyIP Guest Series | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • IPAB on Payyannur Ring
    [*S lightly long post] Background: The Intellectual Property Appellate Board (“ IPAB ”), in its recent order in SubhashJewellery v. Payyan...
  • Guest Post: Intermediary liability in defamation cases - Parle, Mouthshut & Visakha cases to clarify the law
    Chaitanya Ramachandran, who has blogged for us previously over here and here , has sent us this excellent guest post analyzing the extent of...
  • IP Research Assistant position at IIT, Madras
    Feroz Ali Khader, MHRD IP Chair at the Indian Institute of Technology (IIT) Madras, is looking for research assistants to work on various is...
  • Dorling Kindersley v. Sanguine Technical Publishers
    A recent Delhi High Court order passed on 21 January, 2013  with respect to copyright licensing has come to our notice. An analysis of the j...
  • Call for Papers: IIT Bombay and MHRD jointly announce the 2nd International Conference on Management of Intellectual Property and Strategy
    The readers may be interested to know that the Shailesh J. Mehta School of Management of IIT Bombay is geared up to host, in collaboration w...
  • SpicyIP Tidbit: ALCS August Distribution
    In the UK, the Authors' Licensing and Collecting Society is an organization run and owned by writers that collects money due to its mem...
  • Delhi HC rejects the "Hot News" Doctrine: A Summary
    The applicability of the Hot News doctrine was rejected recently in a landmark ruling delivered by Justice Bhat of the Delhi HC. This post i...
  • Satyajit Ray's sketches and copyright controversies
    A copyright row appears to have started between the Satyajit Ray Society and the Delhi Art Gallery, that is organising a countrywide exhibit...
  • Thalappakatti biryani trademark row
    The southern district of Dindigal in Tamil Nadu occupies a special place in the hearts of biryani lovers. In the late 1950s, one Nagasamy N...
  • Karnataka High Court temporarily restrains German company from exploiting trade secrets of Homag India
    Image from here In an interesting judgment dated 10th October, 2012 the Karnataka High Court, sitting at Bangalore, has passed an interim in...

Categories

  • 126 (1)
  • 3(d) (4)
  • 3(f) (1)
  • 3(i) (1)
  • 3(k) (2)
  • Academic Writing (1)
  • access (10)
  • access to food (1)
  • access to health (3)
  • AIA (1)
  • AIDS/HIV (3)
  • Antitrust (2)
  • Bajaj v LML (1)
  • Basmati Row (2)
  • Biological Diversity (5)
  • Biologics (2)
  • biopiracy (4)
  • biotech (7)
  • Bollywood (25)
  • Broadcasters Rights (5)
  • Budget (1)
  • business method patent (2)
  • Call for papers (2)
  • Cipla (2)
  • Comparative Advertising (4)
  • Competition law (8)
  • Compulsory Licensing (27)
  • condonation of delay (1)
  • Conference (4)
  • Constitution (12)
  • Contracts (1)
  • Controller's decisions (8)
  • Copyright (112)
  • Copyright Amendment Bill 2010 (23)
  • copyright board (4)
  • Copyright Exceptions (6)
  • copyright office (1)
  • Copyright Rules (2013) (5)
  • Copyright Societies (9)
  • Counterfeiting (1)
  • creativity (1)
  • Cross Retaliation (1)
  • csir (4)
  • d (1)
  • D.U. Photocopy Case (16)
  • Darjeeling Tea (3)
  • Data Exclusivity (2)
  • Database (1)
  • DCGI (2)
  • decompilation (2)
  • defamation (9)
  • Designs (3)
  • Designs Act (3)
  • Differential Pricing (2)
  • Dilution (1)
  • Disabilities (3)
  • Disability (2)
  • DMCA (2)
  • Doha Declaration (1)
  • Domain Names (2)
  • Draft Policy of the Indian Government (2)
  • DRM (1)
  • Drug Regulation (7)
  • education (12)
  • Enercon (1)
  • Enforcement (1)
  • EU (2)
  • ex parte (2)
  • exhaustion (3)
  • Exhaustion of Rights (2)
  • Fair Dealing (8)
  • Fair Use (11)
  • Federal Circuit (1)
  • Fees (3)
  • FICCI (7)
  • FRAND (2)
  • free trade agreement (3)
  • FTA (3)
  • G.I. Registry (4)
  • gene sequences (3)
  • Generic medicine (4)
  • Geographical Indication (14)
  • Gilead (1)
  • Glenmark (5)
  • Gopika (34)
  • Guest post (11)
  • guidelines (1)
  • GWU-CII (1)
  • Herceptin (1)
  • hot news (3)
  • ICANN (1)
  • incremental innovation (1)
  • independence (1)
  • india (5)
  • Indian Government (1)
  • Indian patent litigation (27)
  • Indian Pharma (35)
  • Injunction (10)
  • Innovation (7)
  • INTA (1)
  • Intermediaries (10)
  • internet (11)
  • Internet Access Providers (IAPs) (5)
  • Internet Censorship (7)
  • IP scholarship (3)
  • IP aware (4)
  • IP Course (3)
  • IP Education (1)
  • IP Policy (11)
  • IP update (4)
  • ip writing competition (1)
  • IPAB (34)
  • ipchair (1)
  • IPO (1)
  • IPRS (5)
  • IT Act (1)
  • Journal (2)
  • judicial independence (3)
  • Jurisdiction (1)
  • Kruttika (4)
  • Legal Education (3)
  • Legal Research Tools (1)
  • Legal Scholarship (2)
  • library (2)
  • Licensing (7)
  • Madhulika (20)
  • mathematical methods (1)
  • Media law (3)
  • medical method (1)
  • Merck (4)
  • mhrd ip chair (1)
  • Microsoft (3)
  • Middle Path (1)
  • Moral Rights (2)
  • Movies (18)
  • musical work (2)
  • nanotechnology (1)
  • Natco (3)
  • natco defamation suit (5)
  • natco vs bayer (4)
  • need for transparency (1)
  • Novartis (8)
  • Novartis patent case in India (11)
  • NPEs (2)
  • nujs (1)
  • NUJS Conference (2)
  • Obituary (1)
  • obviousness (7)
  • Off-Topic (2)
  • online course (4)
  • Open Access (6)
  • Open Source (2)
  • Opposition (3)
  • Parallel Imports (4)
  • Parliament (1)
  • passing off (5)
  • Patent (52)
  • Patent act (10)
  • patent agent (5)
  • patent agent exam (9)
  • patent agent exam qualifications (3)
  • patent infringement (5)
  • Patent Licensing (2)
  • Patent litigation (2)
  • Patent Office (19)
  • patent pool (3)
  • Patent Prosecution (7)
  • Patent rules (2)
  • Patent Strategies (8)
  • Patents (9)
  • pegasus (1)
  • Personality Rights (1)
  • Pfizer (1)
  • Pharma (18)
  • Piracy (5)
  • plagiarism (3)
  • Plant Variety Protection (2)
  • post grant (1)
  • Prashant (2)
  • Preventive Detention (1)
  • Price Control (6)
  • prior publication (1)
  • Privacy (3)
  • Prizes (1)
  • public health (3)
  • Public Interest (4)
  • Publicity Rights (4)
  • Publishing (3)
  • radio (2)
  • Rajiv (18)
  • Rectification Petition (2)
  • Rejection (1)
  • research (3)
  • reverse engineering (2)
  • revocation (4)
  • rip (1)
  • Roche (2)
  • Roche vs Cipla (1)
  • Royalty (2)
  • RTI (2)
  • Scholarship (4)
  • section 16 (1)
  • Section 3(d) (7)
  • section 8 (6)
  • shamnad (11)
  • Shan Kohli (4)
  • Shouvik Kumar Guha (30)
  • Smartphones/Tablets (2)
  • Social Innovation (1)
  • Software (10)
  • software enforcement (3)
  • software patent (3)
  • Special 301 Report (1)
  • Spicy Tidbits (6)
  • spicyip (1)
  • SpicyIP Accolades (1)
  • SpicyIP Announcements (9)
  • SpicyIP Case (1)
  • SpicyIP Cases (3)
  • spicyip commiseration (1)
  • SpicyIP Events (11)
  • SpicyIP Fellowship (5)
  • SpicyIP Guest Series (22)
  • SpicyIP Interview (2)
  • SpicyIP Jobs (4)
  • SpicyIP Jobs/General (2)
  • SpicyIP Review (1)
  • SpicyIP Tidbits (11)
  • SpicyIP Weekly Review (27)
  • Statutory Licensing (1)
  • STI Policy 2013 (4)
  • Sugen (3)
  • Supreme Court of India (5)
  • Swaraj (19)
  • Tarnishment (1)
  • Technology (6)
  • Technology Transfer (5)
  • TKDL (5)
  • TPP (1)
  • trade (4)
  • Trade Secret Protection (1)
  • Trademark (59)
  • Trademark dilution (1)
  • Trademark Registry (9)
  • Traditional Knowledge (7)
  • Transparency (5)
  • treaty (1)
  • trial (1)
  • tribunals (2)
  • TRIPS (11)
  • UK (3)
  • unfair competition (5)
  • UNFCCC (1)
  • Universities Research and Innovation Bill (2)
  • US (1)
  • US Patent Reform (1)
  • US Supreme Court (3)
  • viva (3)
  • WIPO (5)
  • Working a Patent (2)
  • Workshop (4)
  • writ (1)
  • WTO (1)

Blog Archive

  • ▼  2013 (364)
    • ►  September (13)
    • ►  August (41)
    • ►  July (36)
    • ►  June (36)
    • ►  May (32)
    • ▼  April (51)
      • Spicy IP Weekly Review: 4th Week of April, 2013
      • Guest Post: A look at the new notice and takedown ...
      • The patent litigation bug bites Indian pharma comp...
      • DU Copyright Controversy continues: Media joins th...
      • SPICY IP TIDBIT: IPAB reverts “DARJEELING LOUNGE” ...
      • SpicyIP Tidbit: SC stays release of Zanjeer 2.0
      • Hindu-Microsoft spar over AICTE story
      • The Kit Kat Trademark Dispute
      • Oops! IPO did it again: IPAB pulls up patent offic...
      • Guest Post: T-Series’ Constitutional Challenge to ...
      • SpicyIP Tidbit: Controller General restores name o...
      • SpicyIP Tidbit: Update on the Indo-EU FTA negotiat...
      • UK Supreme Court relieves internet users of the th...
      • Guest Post: Are Genes Eligible for Patents in the ...
      • Academics "Speak" Out in Coursepack Copyright Case
      • SPICY IP TIDBIT: Tea Board refused interim injunct...
      • Scoping the constitutional challenges against the ...
      • Guest Post: US Supreme Court hears oral arguments ...
      • IPAB complains, yet again, about lack of resources...
      • Publishers Support Fair Use. Really?
      • The Competition Commission tightens the 'noose' ar...
      • Does the Madras High Court judgment on S. 126 allo...
      • Call for Papers: NLSIU announces Consilience 2013 ...
      • 'Hamara Bajaj'- infringement of trademark of Bajaj...
      • Nautanki Saala: interim relief rejected by the Bom...
      • Delhi High Court scheduled to hear 3 petitions cha...
      • Victory has a thousand fathers – CPI(M) stakes cla...
      • Delhi HC on trademark protection for domain name
      • Madras High Court strikes down amendment to S.126 ...
      • Zanjeer Battle Continues: Scriptwriters Javed Akht...
      • CPI(M): Government negotiating adverse FTA terms
      • India Joins the International Trademark System
      • Thalappakatti biryani trademark row
      • SpicyIP Weekly Review (April- Week 1)
      • FICCI announces online certificate course on IPR a...
      • Investors protest Rise in Royalty Rates paid by As...
      • The salt form jinx:Delhi HC denies interim relief ...
      • Court Stays the Screeening of Ketan Mehta's Film
      • Deconstructing the judgment of the Supreme Court i...
      • Ramesh Sippy faces setback: Bombay High Court allo...
      • Bombay High Court paves the way for the release of...
      • Bombay HC rules on Zanjeer Controversy
      • FICCI announces online certificate course on intel...
      • SpicyIP Weekly Review(March- Week 5)
      • Spicy IP tidbit:Merck files patent infringement su...
      • Patent war intensifies: Glenmark launches generic ...
      • Clarification: Trademark Infringement Suit against...
      • EU gaining a double benefit: Free Trade and GI pro...
      • Supreme Court rejects bid by Novartis to patent Gl...
      • Increased copyright prices of vintage Bollywood so...
      • Officer's Choice v. Original Choice: IPAB allows C...
    • ►  March (66)
    • ►  February (40)
    • ►  January (49)
  • ►  2012 (131)
    • ►  December (29)
    • ►  November (42)
    • ►  October (50)
    • ►  September (10)
Powered by Blogger.